
Epizyme EPZM
Quarterly report 2022-Q2
added 08-09-2022
Epizyme Long Term Debt Current 2011-2025 | EPZM
Annual Long Term Debt Current Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.15 M | 4.66 M | 3.04 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.66 M | 3.04 M | 3.95 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
425 K | $ 4.75 | 1.61 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
481 K | $ 3.29 | -2.08 % | $ 254 M | ||
|
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 25.32 | -2.24 % | $ 1.23 B | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 209.8 | -0.17 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
433 K | $ 1.31 | -1.88 % | $ 7.14 M | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.34 | -2.47 % | $ 8.04 B | ||
|
AstraZeneca PLC
AZN
|
339 M | $ 89.69 | -0.67 % | $ 96.9 B | ||
|
Anika Therapeutics
ANIK
|
1.6 M | $ 9.55 | 0.58 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | ||
|
Benitec Biopharma
BNTC
|
354 K | $ 12.34 | -4.78 % | $ 508 M | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.35 | 3.0 % | $ 14.8 M | ||
|
Baudax Bio
BXRX
|
5.6 M | - | 0.59 % | $ 63 K | ||
|
ChromaDex Corporation
CDXC
|
982 K | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
9.45 M | $ 568.91 | -2.09 % | $ 43.1 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 0.28 | -2.28 % | $ 609 M | ||
|
Catalyst Biosciences
CBIO
|
210 K | $ 14.62 | -4.54 % | $ 962 M | ||
|
Cerus Corporation
CERS
|
2.28 M | $ 2.19 | 1.63 % | $ 404 M | ||
|
Caladrius Biosciences
CLBS
|
137 K | - | -16.75 % | $ 25.8 M | ||
|
Biogen
BIIB
|
86.4 M | $ 174.71 | 1.28 % | $ 25.4 B | ||
|
BioVie
BIVI
|
74.5 K | $ 1.46 | -3.61 % | $ 2.16 M | ||
|
Celldex Therapeutics
CLDX
|
1.45 M | $ 27.71 | -0.82 % | $ 1.78 M | ||
|
Cortexyme
CRTX
|
64 K | - | -1.05 % | $ 67.1 M | ||
|
Cellectar Biosciences
CLRB
|
59 K | $ 3.62 | -4.86 % | $ 44.2 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
3.5 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 11.45 | 0.09 % | $ 741 M | ||
|
BioNTech SE
BNTX
|
39.5 M | $ 94.91 | -1.14 % | $ 27.2 B | ||
|
Eloxx Pharmaceuticals
ELOX
|
712 K | - | -5.68 % | $ 8.28 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K |